Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
tobramycin
Overview
What is TOBREX?
TOBREX (tobramycin ophthalmic ointment) 0.3% is a sterile topical ophthalmic antibiotic formulation prepared specifically for topical therapy of external ophthalmic infections.
Each gram of TOBREX (tobramycin ophthalmic ointment) 0.3% contains: Active:
Preservative:
Inactives:
Tobramycin is a water-soluble aminoglycoside antibiotic active against a wide variety of gram-negative and gram-positive ophthalmic pathogens.
The chemical structure of tobramycin is:
Molecular Formula:
CHNO
Molecular Weight: 467.52
Chemical Name:
0-{3-amino-3-deoxy-α-D-gluco-pyranosyl-(1→4) }-0-{2,6-diamino-2,3,6-trideoxy-α-D-ribohexo-pyranosyl-(1→6) }-2-deoxystreptamine.
What does TOBREX look like?
What are the available doses of TOBREX?
Sorry No records found.
What should I talk to my health care provider before I take TOBREX?
Sorry No records found
How should I use TOBREX?
TOBREX (tobramycin ophthalmic ointment) 0.3 % is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of TOBREX (tobramycin ophthalmic ointment) 0.3%. Clinical studies have shown tobramycin to be safe and effective for use in children.
In mild to moderate disease, apply a half-inch ribbon into the affected eye(s) two or three times per day. In severe infections, instill a half-inch ribbon into the affected eye(s) every three to four hours until improvement, following which treatment should be reduced prior to discontinuation.
How to Apply TOBREX (tobramycin ophthalmic ointment) 0.3%:
1. Tilt your head back.
2. Place a finger on your cheek just under your eye and gently pull down until a ''V'' pocket is formed between your eyeball and your lower lid.
3. Place a small amount (about ½ inch) of TOBREX (tobramycin ophthalmic ointment) 0.3% in the ''V'' pocket. Do not let the tip of the tube touch your eye.
4. Look downward before closing your eye.
What interacts with TOBREX?
Sorry No Records found
What are the warnings of TOBREX?
Sorry No Records found
What are the precautions of TOBREX?
Sorry No Records found
What are the side effects of TOBREX?
Sorry No records found
What should I look out for while using TOBREX?
TOBREX (tobramycin ophthalmic ointment) 0.3 % is contraindicated in patients with known hypersensitivity to any of its components.
NOT FOR INJECTION INTO THE EYE. Sensitivity to topically applied aminoglycosides may occur in some patients. If a sensitivity reaction to TOBREX (tobramycin ophthalmic ointment) 0.3% occurs, discontinue use.
What might happen if I take too much TOBREX?
Clinically apparent signs and symptoms of an overdose of TOBREX (tobramycin ophthalmic ointment) 0.3% (punctate keratitis, erythema, increased lacrimation, edema and lid itching) may be similar to adverse reaction effects seen in some patients.
How should I store and handle TOBREX?
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) []. 3.5 g STERILE ointment supplied in an aluminum tube with a white polyethylene tip and white polyethylene cap (0065-0644-35), containing tobramycin 0.3% (3 mg/g).Storage: Rx Only© 2002, 2018 Alcon, Inc.Revised: April 2018Distributed by:ALCON LABORATORIES, INC.Fort Worth, Texas 76134 USAAlcon A Novartis companyManufactured by:S.A. ALCON-COUVREUR N.V.Puurs, BelgiumT2018-303.5 g STERILE ointment supplied in an aluminum tube with a white polyethylene tip and white polyethylene cap (0065-0644-35), containing tobramycin 0.3% (3 mg/g).Storage: Rx Only© 2002, 2018 Alcon, Inc.Revised: April 2018Distributed by:ALCON LABORATORIES, INC.Fort Worth, Texas 76134 USAAlcon A Novartis companyManufactured by:S.A. ALCON-COUVREUR N.V.Puurs, BelgiumT2018-303.5 g STERILE ointment supplied in an aluminum tube with a white polyethylene tip and white polyethylene cap (0065-0644-35), containing tobramycin 0.3% (3 mg/g).Storage: Rx Only© 2002, 2018 Alcon, Inc.Revised: April 2018Distributed by:ALCON LABORATORIES, INC.Fort Worth, Texas 76134 USAAlcon A Novartis companyManufactured by:S.A. ALCON-COUVREUR N.V.Puurs, BelgiumT2018-303.5 g STERILE ointment supplied in an aluminum tube with a white polyethylene tip and white polyethylene cap (0065-0644-35), containing tobramycin 0.3% (3 mg/g).Storage: Rx Only© 2002, 2018 Alcon, Inc.Revised: April 2018Distributed by:ALCON LABORATORIES, INC.Fort Worth, Texas 76134 USAAlcon A Novartis companyManufactured by:S.A. ALCON-COUVREUR N.V.Puurs, BelgiumT2018-303.5 g STERILE ointment supplied in an aluminum tube with a white polyethylene tip and white polyethylene cap (0065-0644-35), containing tobramycin 0.3% (3 mg/g).Storage: Rx Only© 2002, 2018 Alcon, Inc.Revised: April 2018Distributed by:ALCON LABORATORIES, INC.Fort Worth, Texas 76134 USAAlcon A Novartis companyManufactured by:S.A. ALCON-COUVREUR N.V.Puurs, BelgiumT2018-303.5 g STERILE ointment supplied in an aluminum tube with a white polyethylene tip and white polyethylene cap (0065-0644-35), containing tobramycin 0.3% (3 mg/g).Storage: Rx Only© 2002, 2018 Alcon, Inc.Revised: April 2018Distributed by:ALCON LABORATORIES, INC.Fort Worth, Texas 76134 USAAlcon A Novartis companyManufactured by:S.A. ALCON-COUVREUR N.V.Puurs, BelgiumT2018-303.5 g STERILE ointment supplied in an aluminum tube with a white polyethylene tip and white polyethylene cap (0065-0644-35), containing tobramycin 0.3% (3 mg/g).Storage: Rx Only© 2002, 2018 Alcon, Inc.Revised: April 2018Distributed by:ALCON LABORATORIES, INC.Fort Worth, Texas 76134 USAAlcon A Novartis companyManufactured by:S.A. ALCON-COUVREUR N.V.Puurs, BelgiumT2018-303.5 g STERILE ointment supplied in an aluminum tube with a white polyethylene tip and white polyethylene cap (0065-0644-35), containing tobramycin 0.3% (3 mg/g).Storage: Rx Only© 2002, 2018 Alcon, Inc.Revised: April 2018Distributed by:ALCON LABORATORIES, INC.Fort Worth, Texas 76134 USAAlcon A Novartis companyManufactured by:S.A. ALCON-COUVREUR N.V.Puurs, BelgiumT2018-303.5 g STERILE ointment supplied in an aluminum tube with a white polyethylene tip and white polyethylene cap (0065-0644-35), containing tobramycin 0.3% (3 mg/g).Storage: Rx Only© 2002, 2018 Alcon, Inc.Revised: April 2018Distributed by:ALCON LABORATORIES, INC.Fort Worth, Texas 76134 USAAlcon A Novartis companyManufactured by:S.A. ALCON-COUVREUR N.V.Puurs, BelgiumT2018-303.5 g STERILE ointment supplied in an aluminum tube with a white polyethylene tip and white polyethylene cap (0065-0644-35), containing tobramycin 0.3% (3 mg/g).Storage: Rx Only© 2002, 2018 Alcon, Inc.Revised: April 2018Distributed by:ALCON LABORATORIES, INC.Fort Worth, Texas 76134 USAAlcon A Novartis companyManufactured by:S.A. ALCON-COUVREUR N.V.Puurs, BelgiumT2018-303.5 g STERILE ointment supplied in an aluminum tube with a white polyethylene tip and white polyethylene cap (0065-0644-35), containing tobramycin 0.3% (3 mg/g).Storage: Rx Only© 2002, 2018 Alcon, Inc.Revised: April 2018Distributed by:ALCON LABORATORIES, INC.Fort Worth, Texas 76134 USAAlcon A Novartis companyManufactured by:S.A. ALCON-COUVREUR N.V.Puurs, BelgiumT2018-303.5 g STERILE ointment supplied in an aluminum tube with a white polyethylene tip and white polyethylene cap (0065-0644-35), containing tobramycin 0.3% (3 mg/g).Storage: Rx Only© 2002, 2018 Alcon, Inc.Revised: April 2018Distributed by:ALCON LABORATORIES, INC.Fort Worth, Texas 76134 USAAlcon A Novartis companyManufactured by:S.A. ALCON-COUVREUR N.V.Puurs, BelgiumT2018-303.5 g STERILE ointment supplied in an aluminum tube with a white polyethylene tip and white polyethylene cap (0065-0644-35), containing tobramycin 0.3% (3 mg/g).Storage: Rx Only© 2002, 2018 Alcon, Inc.Revised: April 2018Distributed by:ALCON LABORATORIES, INC.Fort Worth, Texas 76134 USAAlcon A Novartis companyManufactured by:S.A. ALCON-COUVREUR N.V.Puurs, BelgiumT2018-303.5 g STERILE ointment supplied in an aluminum tube with a white polyethylene tip and white polyethylene cap (0065-0644-35), containing tobramycin 0.3% (3 mg/g).Storage: Rx Only© 2002, 2018 Alcon, Inc.Revised: April 2018Distributed by:ALCON LABORATORIES, INC.Fort Worth, Texas 76134 USAAlcon A Novartis companyManufactured by:S.A. ALCON-COUVREUR N.V.Puurs, BelgiumT2018-30
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
In Vitro Data: In vitro
S. aureus
S. epidermidis
Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some .
Pseudomonas aeruginosa
Escherichia coli, Klebsiella pneumoniae
Enterobacter aerogenes
Proteus mirabilis
Morganella morganii
Proteus vulgaris
Haemophilus influenzae
H. aegyptius
Moraxella lacunata
Acinetobacter calcoaceticus
Neisseria species
Non-Clinical Toxicology
TOBREX (tobramycin ophthalmic ointment) 0.3 % is contraindicated in patients with known hypersensitivity to any of its components.NOT FOR INJECTION INTO THE EYE. Sensitivity to topically applied aminoglycosides may occur in some patients. If a sensitivity reaction to TOBREX (tobramycin ophthalmic ointment) 0.3% occurs, discontinue use.
Careful observation is required when amantadine hydrochloride is administered concurrently with centralnervous system stimulants.
Agents with anticholinergic properties may potentiate the anticholinergic-like side effects of amantadine.
Coadministration of thioridazine has been reported to worsen the tremor in elderly patients with Parkinson's disease, however, it is not known if other phenothiazines produce a similar response.
Coadministration of Dyazide (triamterene/ hydrochlorothiazide) resulted in a higher plasma amantadine concentration in a 61-year-old man receiving amantadine hydrochloride 100 mg TID. for Parkinson's disease. It is not known which of the components of Dyazide contributed to the observation or if related drugs produce a similar response.
Coadministration of quinine or quinidine with amantadine was shown to reduce the renal clearance of amantadine by about 30%.
The concurrent use of amantadine hydrochloride with live attenuated influenza vaccine (LAIV) intranasal has not been evaluated. However, because of the potential for interference between these products, LAIV should not be administered within 2 weeks before or 48 hours after administration of amantadine hydrochloride, unless medically indicated. The concern about possible interference arises from the potential for antiviral drugs to inhibit replication of live vaccine virus. Trivalent inactivated influenza vaccine can be administered at any time relative to use of amantadine hydrochloride.
General:
Cross-sensitivity to other aminoglycoside antibiotics may occur; if hypersensitivity develops with this product, discontinue use and institute appropriate therapy.
Patients should be advised not to wear contact lenses if they have signs and symptoms of ocular infections.
The most frequent adverse reactions to TOBREX (tobramycin ophthalmic ointment) 0.3% are hypersensitivity and localized ocular toxicity, including lid itching and swelling, and conjunctival erythema. These reactions occur in less than three of 100 patients treated with TOBREX (tobramycin ophthalmic ointment) 0.3%. Similar reactions may occur with the topical use of other aminoglycoside antibiotics. Other adverse reactions have not been reported from TOBREX (tobramycin ophthalmic ointment) 0.3% therapy; however, if topical ocular tobramycin is administered concomitantly with systemic aminoglycoside antibiotics, care should be taken to monitor the total serum concentration. In clinical trials, TOBREX (tobramycin ophthalmic ointment) 0.3 % produced significantly fewer adverse reactions (3.7%) than did GARAMYCIN Ophthalmic Ointment (10.6%).
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
514Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).